Patrick Hwu: Identifying neoantigens from metastatic tumors
Patrick Hwu, President and CEO at Moffitt Cancer Center, shared a recent article by Vid Leko et al. on LinkedIn:
“Immunotherapies targeting neoantigens can be effective in mediating long-term durable responses in advanced cancer patients. However, identifying these neoantigens from metastatic tumors can be logistically challenging.
In this study, investigators looked at whether archived, preserved primary tumor samples could be used for neoantigen discovery.
The study found that primary FFPE tumor samples could be used to discover most of the neoantigens present in metastatic tumors and even unique neoantigens not present in metastatic tumors.
This approach would reduce the need for additional, sometimes complicated resections and expedite the time to treatment! These promising findings could pave the way for more accessible and personalized therapies.
Here’s the link to the full study.”
Utilization of primary tumor samples for cancer neoantigen discover
Authors: Vid Leko et al
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023